Nicotine Replacement Therapy for Smoking Cessation
Trial Summary
What is the purpose of this trial?
The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessment will be completed. Participants who are eligible at the Intake will be randomized (within site and Intake Group) to R or IP Treatment and Assessment Groups. Participants will be followed for 3 months.
Will I have to stop taking my current medications?
If you are currently using any smoking cessation or antipsychotic medications, you will need to stop taking them to participate in this trial.
What data supports the effectiveness of the treatment Combination Nicotine Replacement Therapy for smoking cessation?
Is nicotine replacement therapy generally safe for humans?
How is combination nicotine replacement therapy different from other smoking cessation treatments?
Combination nicotine replacement therapy is unique because it uses two forms of nicotine delivery: a patch for steady, slow release and an inhaler for quick relief of cravings. This dual approach can be more effective than using just one method, as it addresses both constant and sudden urges to smoke.125910
Eligibility Criteria
This trial is for individuals who want to quit smoking and are willing to try nicotine replacement therapy. Participants must pass a basic eligibility screen and can attend either remote or in-person sessions. Specific inclusion and exclusion criteria details were not provided.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intake
Detailed consent and eligibility assessment completed; participants randomized to treatment groups
Treatment
Participants receive treatment and assessment visits; adherence and retention monitored
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Combination Nicotine Replacement Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
State University of New York at Buffalo
Lead Sponsor
Medical University of South Carolina
Collaborator
University of Pennsylvania
Collaborator
University of Alabama at Birmingham
Collaborator
National Center for Advancing Translational Sciences (NCATS)
Collaborator
Abramson Cancer Center at Penn Medicine
Collaborator